期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Expert consensus on the glycemic management of critically ill patients 被引量:18
1
作者 Zhixiong Wu Jiao Liu +19 位作者 Dong Zhang Kai Kang xiangrong zuo Qianghong Xu Aijun Pan Wei Fang Fen Liu You Shang Haiyan Yin Juntao Hu Jinglun Liu Jiangquan Fu Wei Zhang Yuan Zong Min Shao Feng Zhao Mei Meng Yanfei Mao Yingchuan Li Dechang Chen 《Journal of Intensive Medicine》 2022年第3期131-145,共15页
Introduction The incidence of hyperglycemia is 40-60%in critically ill patients and is up to 60-80%in those who have undergone car-diac surgery.[1]The results of an epidemiological study in the United States showed th... Introduction The incidence of hyperglycemia is 40-60%in critically ill patients and is up to 60-80%in those who have undergone car-diac surgery.[1]The results of an epidemiological study in the United States showed that 28.6%of diabetic patients and 9.3%of non-diabetic patients had elevated mean daily glucose on the day of ICU admission.[2]In critically ill patients,elevated blood glucose is primarily the result of stress,and stress-induced hy-perglycemia is an independent risk factor associated with prog-nosis,regardless of a previous diagnosis of diabetes.Nutritional therapy has become an integral treatment option for patients in the ICU,[3,4]though nearly 30%of patients with enteral nu-trition and 44-50%with parenteral nutrition(PN)experience elevated glucose.[5,6]Intensive insulin therapy(IIT)is an impor-tant treatment for controlling hyperglycemia in critically ill pa-tients,but it also carries a corresponding risk of hypoglycemia. 展开更多
关键词 PATIENTS ELEVATED DIAGNOSIS
原文传递
头孢他啶/阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌感染的研究进展
2
作者 刘佩本 石颖 +1 位作者 左祥荣 曹权 《中华重症医学电子杂志》 CSCD 2022年第1期67-73,共7页
耐碳青霉烯类肠杆菌科细菌(CRE)感染现呈逐年上升的趋势,临床治疗手段有限,病死率高,形势严峻。而头孢他啶/阿维巴坦(CAZ-AVI)作为一种新型的β-内酰胺类抗生素与β-内酰胺酶抑制剂的复合制剂,其批准的适应证包括复杂性尿路感染、复杂... 耐碳青霉烯类肠杆菌科细菌(CRE)感染现呈逐年上升的趋势,临床治疗手段有限,病死率高,形势严峻。而头孢他啶/阿维巴坦(CAZ-AVI)作为一种新型的β-内酰胺类抗生素与β-内酰胺酶抑制剂的复合制剂,其批准的适应证包括复杂性尿路感染、复杂性腹腔内感染及呼吸机相关性肺炎,具有广谱、高效、作用部位广、安全性高等特点,对CRE具有较高的体外活性,成为治疗CRE感染的新选择。本文总结CAZ-AVI的药理学特点、临床应用、综合评价等方面的研究进展,探讨其临床治疗CRE感染的合理性、有效性和安全性,以期为CRE感染的治疗和CAZ-AVI的临床应用提供依据。 展开更多
关键词 头孢他啶/阿维巴坦 耐碳青霉烯类肠杆菌 多重耐药菌 细菌感染
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部